Maze Therapeutics (MAZE) Research & Development (2024 - 2026)
Maze Therapeutics (MAZE) posted Research & Development of $34.1 million for Q1 2026, up 23.86% sequentially from $27.6 million in Q4 2025, and up 23.81% YoY from $27.6 million in Q1 2025.
Maze Therapeutics (MAZE) Research & Development (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Research & Development for 3 years, with the latest figure at $34.1 million in Q1 2026.
- Quarterly Research & Development rose 23.81% year-over-year to $34.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $115.0 million (up 28.94% YoY) and the FY2025 annual result came in at $108.4 million, up 29.88% from the prior year.
- Research & Development rose to $34.1 million in Q1 2026 per MAZE's latest filing, from $27.6 million in the prior quarter.
- Over five years, Research & Development peaked at $34.1 million in Q1 2026 and troughed at $19.5 million in Q2 2024.
- A 3-year average of $25.1 million and a median of $25.2 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2025 and 2026: Research & Development jumped 43.8% in 2025, then increased 23.81% in 2026.
- Over 3 years, Research & Development stood at $22.2 million in 2024, then grew by 24.1% to $27.6 million in 2025, then climbed by 23.86% to $34.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $34.1 million, $27.6 million, and $25.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 34.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.94 Mn |
| Mar 31, 2026 | 34.15 Mn |
| Dec 31, 2025 | 27.57 Mn |
| Sep 30, 2025 | 25.19 Mn |
| Jun 30, 2025 | 28.11 Mn |
| Mar 31, 2025 | 27.58 Mn |
| Dec 31, 2024 | 22.22 Mn |
| Sep 30, 2024 | 19.86 Mn |
| Jun 30, 2024 | 19.55 Mn |
| Mar 31, 2024 | 21.88 Mn |